Testing for Alzheimer Disease in Asymptomatic Adults.

Testing for Alzheimer disease biomarkers in asymptomatic adults has uncertain prognostic value and may lead to significant personal and social repercussions.

• Why it matters: Understanding the implications of early biomarker testing is crucial because it can influence individuals' psychological well-being and social circumstances, yet its predictive accuracy remains unclear.
• What they did: The authors review the current state of biomarker testing in asymptomatic adults and highlight potential consequences, including insurance, employment, financial, and psychological impacts of positive results.
• The result: The discussion underscores the need for caution and further research before widespread implementation of Alzheimer biomarker testing in asymptomatic populations.